Pre-earnings brief
Reports
Thu, Dec 1, 2022
Est. EPS
—
Est. revenue
—
Implied move
±18.2%
EPS beat rate
67%
Legend Biotech Corporation is a biotechnology company focused on developing innovative cell therapies for cancer treatment. As part of the health care sector, it plays a crucial role in advancing medical solutions that can potentially improve patient outcomes in oncology.
Last quarter
In the last quarter, Legend Biotech reported an EPS of -$0.16, outperforming expectations by 44%. However, revenue details were not disclosed, leaving some uncertainty about overall performance.
EPS beat streak
1Q
EPS beat rate
67%
Avg EPS surprise
+12.73%
Avg 1-day reaction
+3.44%
Investors are cautiously optimistic about Legend Biotech's upcoming earnings, especially after a positive surprise last quarter. However, the lack of guidance creates uncertainty.
Bull case
If the company continues to show improved EPS and reveals strong revenue growth, it could signal robust demand for its therapies, boosting investor confidence.
Bear case
Conversely, if the company fails to meet expectations or provides no guidance, it may lead to a decline in stock price as investors reassess their outlook.
The print will turn on these.
Q1
What is the updated EPS forecast for the next quarter?
This will provide insight into the company's profitability trajectory and how it is managing costs moving forward.
Q2
Will there be any guidance on revenue growth for the upcoming quarters?
Revenue guidance is critical for understanding market demand for Legend's therapies and overall business health.
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Why consensus could be wrong
The market may be underestimating the potential for Legend Biotech to surprise positively due to its recent operational improvements.
Supporting evidence
Last quarter's EPS surprise of 44% indicates potential for continued positive momentum.
Options pricing suggests a significant move, indicating that traders are expecting volatility, which could favor a positive outcome.
Key risk
If the EPS comes in better than expected, it could shift the market's perception of the company's growth potential.
Pre-commit to what would confirm each case.
This quarter's performance is pivotal as it will either reinforce the recent positive trend or highlight persistent issues.
Bull confirmed if
An EPS of -$0.10 or better would confirm the bull case, indicating improved profitability.
Bear confirmed if
An EPS worse than -$0.20 would confirm the bear case, suggesting ongoing challenges in managing costs.
What the market is pricing for the move.
Implied Move
±18.23%
Historical Avg
±6.1%
The options market is pricing in a significant move, suggesting that traders anticipate volatility around the earnings report.
Options are pricing ±18.2% while LEGN has averaged ±6.1% over the last 6 prints — setup is pricing rich.
ATM IV
1.3%
30d HV
47.3%
Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.
Bought
$0.00
0 sh
0 insiders
Sold
$258,920.20
27,370 sh
1 insider
Net
$258,920.20
Net selling
Most Active Insiders· 1 open-market trade
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Legend Biotech beats expectations, history suggests a potential stock increase of around 1.71%, confirming positive momentum.
In line / cautious
A cautious in-line report could lead to muted reactions, reflecting uncertainty in future guidance.
Miss
If the company misses expectations, history suggests a possible decline of around 6.91%, indicating investor disappointment.
The lines on the call that would change the story.
$258,920.20
Net selling
Recent Transactions
Sep 29, 2026 · @ $9.46
27,370 sh
$258,920.20
Open-market trades only (Form 4 codes P/S). Awards, exercises, and tax-withholding excluded as routine compensation noise.